ArticleOncotarget2015

Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.

Min Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.